Literature DB >> 28926926

Protective effects of aloperin on monocroline-induced pulmonary hypertension via regulation of Rho A/Rho kinsase pathway in rats.

Fan Wu1, Wanxia Yao1, Jiamei Yang1, Min Zhang1, Yanping Xu2, Yinju Hao1, Lin Yan3, Yang Niu4, Tao Sun5, Jianqiang Yu6, Ru Zhou7.   

Abstract

Pulmonary hypertension (PH) is fatal disease which closely involves Rho A/ Rho kinsase (ROCK) pathway. Aloperine is a main active alkaloid extracted from Sophora alopecuroides, which is a traditional Chinese herbal medicine that has been used widely. However, the effects of this alkaloid on pulmonary hypertension and its mechanisms remain unclear. Therefore, this study is designed to investigate whether aloperine has protective effects on PH induced by monocrotaline, whether these effects may be related to regulation of RhoA/ROCK pathway in rats. Pulmonary hypertension was induced by monocrotaline (60mg/kg), and subsequently oral administration of aloperine (25, 50, 100mg/kg/day) for 21 days. At the end of the experiment, rats were underwent hemodynamic and morphologic assessments. At same time, the expression of Rho A, ROCK1, ROCK2, as well as activities of ROCK in the lung of rat has been detected. Afterwards, the expression of p27kip1, Bax, Bcl-2, which was the downstream proliferation and apoptosis factors of ROCK, were tested. The result indicted that aloperine treatment showed significantly improvement in hemodynamic and pathomorphologic data. Moreover, the reduction in expression of Rho A, ROCK1, ROCK2, and suppression in activities of ROCK were found in rat lungs after aloperine treatment. Furthermore, aloperine also alleviated the MCT-induced changes of p27kip1, Bax and Bcl-2. In summary, this study indicates that aloperine have protective effects on monocrotaline-induced PH. And these effects may be partially related to RhoA/ROCK pathway. Thus, aloperine could be considered a possible therapeutic strategy for PH.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Aloperine; Monocrotaline; Pulmonary hypertension; Rho A; Rho kinase

Mesh:

Substances:

Year:  2017        PMID: 28926926     DOI: 10.1016/j.biopha.2017.08.126

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Protective Effects of 18β-Glycyrrhetinic Acid on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats.

Authors:  Min Zhang; Zhi Chang; Fang Zhao; Peng Zhang; Yin-Ju Hao; Lin Yan; Ning Liu; Jun-Li Wang; Lei Bo; Ping Ma; Wei Zhou; Xuan Ma; Qing-Bin Xu; Ru Zhou
Journal:  Front Pharmacol       Date:  2019-01-22       Impact factor: 5.810

2.  Inhibitory effects of formononetin on the monocrotaline‑induced pulmonary arterial hypertension in rats.

Authors:  Yonghui Wu; Changhong Cai; Lebing Yang; Yijia Xiang; Huan Zhao; Chunlai Zeng
Journal:  Mol Med Rep       Date:  2020-01-03       Impact factor: 2.952

3.  The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats.

Authors:  Hiroki Shoji; Yoko Yoshida; Takayuki Jujo Sanada; Akira Naito; Junko Maruyama; Erquan Zhang; Kengo Sumi; Seiichiro Sakao; Kazuo Maruyama; Hiroyoshi Hidaka; Koichiro Tatsumi
Journal:  Cells       Date:  2021-12-27       Impact factor: 6.600

Review 4.  Traditional Herbal Medicine Discovery for the Treatment and Prevention of Pulmonary Arterial Hypertension.

Authors:  Zhifeng Xue; Yixuan Li; Mengen Zhou; Zhidong Liu; Guanwei Fan; Xiaoying Wang; Yan Zhu; Jian Yang
Journal:  Front Pharmacol       Date:  2021-11-09       Impact factor: 5.810

Review 5.  ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension.

Authors:  Tadeu L Montagnoli; Jaqueline S da Silva; Susumu Z Sudo; Aimeé D Santos; Gabriel F Gomide; Mauro P L de Sá; Gisele Zapata-Sudo
Journal:  Cells       Date:  2021-06-30       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.